In Vivo Gene Editing of T, NK, and Myeloid Cells: Prospects for Immunotherapy and Validation Challenges
Efforts to move immune-cell engineering into the body
“In vivo immunoengineering,” which directly reprograms immune cells inside the patient’s body, is being studied as a way to reduce the manufacturing and logistics burden of cellular immunotherapy. A review published in the March 2026 issue of Med summarizes delivery technologies, therapeutic constructs, and challenges in assessing safety and efficacy for in vivo gene editing of T cells, NK cells, and myeloid cells. It is a review of relevant approaches and challenges in clinical translation, not an individual experiment or clinical trial reporting new therapeutic effects.
The authors explain that cell-based immunotherapies have shown results in treating cancer and other diseases through precise and durable tumor targeting, but that approaches involving immune-cell manipulation outside the body face logistical, economic, and manufacturing constraints. In vivo immunoengineering aims to overcome these constraints by directly modifying cells inside the patient. However, the supplied abstract does not provide data to assess the extent of any reduction in manufacturing time or cost.
Delivery challenges to address alongside gene editing
The review covers delivery platforms and therapeutic constructs for in vivo gene editing. It examines both how the components needed for treatment are delivered into the body and how the genes function after delivery. The therapeutic goals described by the authors are to reconfigure tumors and their surrounding environment—the “tumor microenvironment”—in situ and to restore immune responses against tumors.
The abstract does not specify particular carrier or editing-tool types, or delivery and editing efficiencies for different cell types. Therefore, there is no basis for presenting this review as a success story for nonviral nanoparticles or a single CRISPR-based platform. Reconfiguration of the tumor microenvironment and restoration of antitumor immunity are also presented as goals of this approach; the abstract does not indicate the magnitude or timing of effects observed in any specific experiment.
Where do the delivered components reach, and how do they work?
The authors identify biodistribution, control of gene expression, immunogenicity, and tumorigenic potential as key areas for assessing safety and efficacy. Biodistribution concerns which parts of the body the delivered components reach, while control of gene expression concerns regulating how genes function. Immunogenicity is the potential to trigger an immune response, and tumorigenic potential refers to risks related to tumor development.
These are challenges that should be considered together when evaluating in vivo immune-cell editing. The abstract presents them as topics for discussion, but provides no quantitative results showing precise control of distribution or expression, or reductions in immune-response or tumor-development risks. Assessing the performance and safety of a specific technology requires examining the study’s comparison conditions, endpoints, and observation period.
Questions remaining after early clinical efforts
The review also discusses early clinical efforts and barriers to advancing toward patient treatment. However, the supplied abstract does not report the phase of any individual trial, patient characteristics, participant numbers, treatment responses, or adverse events. Whether any specific clinical trial is currently ongoing, or its clinical utility, cannot be determined from this material alone.
In vivo immunoengineering is a development direction intended to address manufacturing and logistics constraints in cell therapy. To assess its potential for future clinical use, it will be necessary to examine how well delivery and gene expression can be controlled and what evidence supports safety and therapeutic effects. This article was based on the supplied Europe PMC bibliographic record and abstract.
The clinical success of cell-based immunotherapies has revolutionized treatment of cancer and other diseases by enabling precise and durable tumor targeting. However, while traditional ex vivo engineering of immune cells has demonstrated promise, these approaches are constrained by logistical, economic, and manufacturing challenges that hinder broad clinical adoption. In vivo immune engineering, which directly reprograms immune cells within the patient's body, is emerging as an attractive alternative to overcome these limitations and directly reshape the tumor microenvironment (TME) in situ and restore antitumor immunity. This review surveys current approaches to overcoming them through in vivo delivery platforms and therapeutic constructs to achieve direct in vivo gene editing. We further discuss key safety and efficacy considerations, such as biodistribution, gene expression control, immunogenicity, and tumorigenicity. Finally, we examine early clinical efforts and translational hurdles in bringing in vivo immune engineering strategies to the bedside.
This review outlines the factors to consider alongside delivery and editing performance when evaluating in vivo immune-cell editing technologies. Biological researchers can assess their potential for clinical translation by considering biodistribution, control of gene expression, immunogenicity, and tumorigenic potential together. It is also important to distinguish the aim of reducing the manufacturing and logistics burden of ex vivo cell manipulation from outcomes that have actually been demonstrated. Follow-up studies should be examined for their target cells and delivery components, comparison conditions, endpoints, and follow-up periods. The supplied abstract points to these areas for review, but does not provide evidence to determine whether a particular platform is superior or whether it reduces costs or improves patient access.